Alternet Systems, Inc. (ALYI) is in the Business of Passing

New Post Public Reply Private Reply Replies (0) Message Board
QualityStocks
Alternet Systems, Inc. (ALYI) is in the Business of Passing the Buck

According to the Federal Bank of New York, there are about $1.2 trillion dollars of U.S. currency in circulation. Every day a significant proportion of that changes hand as individuals and institutions buy and sell, pay bills, and make other money transfers. The payments systems is a behemoth that, in general, operates so smoothly we never even notice it’s there. Yet that near flawless perfection comes at a price that we do pay, more often than not, in the fees that banks and other agents charge to run the system.

The Economist newspaper estimates that one set of agents, or banks, are involved in over $400 trillion of money transfers every year and that, on average, they earn a quarter of one percent (0.25%) on those transfers, which amounts to $1 trillion dollars. That’s a big pie, and it’s a pie that’s aroma has attracted Alternet Systems, Inc. (OTCQB: ALYI).

Alternet Systems invests in multi-channel payment solutions that include both hard and digital currencies. The company offers high-tech solutions to financial organizations that handle payments from point-of-sale devices, smart phones, tablets, PCs, and web-based applications. In August 2015, the company announced that its wholly-owned subsidiary, Alternet Payment Solutions, had signed a strategic partnership with MUXI (a subsidiary of the APPI Group) to provide U.S. payment processors and independent sales organizations a flexible multi-channel point-of-sale payment processing solution. The MUXI platform, known as POSWEB, has been up and running in Brazil for over 12 years. It has been installed in a wide range of outlets, including banks, gas stations, hotels, restaurants, travel agencies, and department stores. Significantly, the platform is employed by international money transfer agents. In all, the MUXI platform boasts over 2.5 million installed terminals.

The future for a fintech company like Alternet is bright. The payments system, dominated by the major banks and the industry giants Visa (NYSE: V) and MasterCard (NYSE: MA), which are known in the trade as ‘rails’, is undergoing a metamorphosis. A recent development is the emergence of online ‘wallets’. A wallet combines the ability to make payments and transfer funds with specialized information such as a user’s shipping address and credit card details. One of the better known wallets is, of course, PayPal (NASDAQ: PYPL), but there’s the already very popular Apple (NASDAQ: AAPL) Pay, Google (NASDAQ: GOOG) Wallet and quite a few others.

Another area of promise is the peer-to-peer fund transfer market pioneered by Venmo, which is now part of PayPal. Venmo is a free digital wallet that allows friends to transfer cash to each other. Another promising skew is the area of web payment platforms – applications that a merchant can install on his website to accept payments. There’s a positive direct relationship between ease of pay and ‘conversion rate’, which considers the proportion of visitors that are ‘converted’ to buyers.

The thrust of Alternet’s strategy is the displacement of the payments process from various forms of specialized hardware and legacy systems. These traditional approaches to payments can be replicated and improved with software solutions. An additional benefit is the portability across various platforms of a software solution. Providing such solutions is Alternet’s vision. This is one area where the company won’t pass the buck.

For more information, visit www.alternetsystems.com

Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com

Alternet Systems Inc (ALYI) Stock Research Links

ALYI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investors Urged to Act as Lawsuit Against Everus Builds

Updated Category News Views 97

Investigation of Claims Against Everus Construction Group Faruqi & Faruqi, LLP, a well-respected national securities law firm, has initiated an investigation into potential claims associated with Everus Construction Group, Inc. (NYSE: ECG). The firm specializes in shareholder rights and is aiming to provide support to affected investors after concerning revelations about...

Continue Reading
Heilongjiang Forum 2025: Elevating Macao's Global Tourism Standing

Updated Category News Views 107

Global Tourism Economy Forum 2025: A Landmark Event The Global Tourism Economy Forum (GTEF) made its notable debut outside of Macao by hosting the 2025 edition in Heilongjiang province, China. This forum gathered influential figures from the tourism sector and various related industries, fostering discussions aimed at exploring new avenues for cooperation and growth....

Continue Reading
Nextracker and T1 Energy Collaboration Drives Solar Growth

Updated Category News Views 198

Nextracker and T1 Energy Join Forces to Strengthen Solar Production Nextracker Inc. (NASDAQ: NXT) has recently established a partnership with T1 Energy Inc. (NYSE: TE) aimed at revolutionizing solar manufacturing. This collaboration will see the integration of Nextracker's cutting-edge steel module frame technology into T1 Energy's upcoming solar manufacturing plant,...

Continue Reading
Nathan Ballentine Steps In as Regional VP at New American Funding

Updated Category News Views 175

New Leadership at New American Funding New American Funding (NAF), a prominent independent mortgage lender, has announced a significant appointment. Nathan Ballentine is joining the team as the Regional Vice President, where he will play a pivotal role in propelling growth and development within the state. His expertise will be crucial as the company seeks to deepen its...

Continue Reading
CSL Behring Secures Approval for ANDEMBRY® in Japan

Updated Category News Views 341

CSL Behring's Recent Approval for ANDEMBRY® CSL Behring has announced a significant medical milestone with the approval of ANDEMBRY® (garadacimab) subcutaneous (S.C.) injection 200mg pens in Japan. This groundbreaking therapy is a first-in-class monoclonal antibody specifically designed to inhibit activated Factor XII (FXIIa), a crucial initiator in the hereditary...

Continue Reading